Recurrence and Prognosis in Intrahepatic Cholangiocarcinoma Patients with Different Etiology After Radical Resection: A Multi-Institutional Study
Qi Li(First Affiliated Hospital of Xi'an Jiaotong University), Zhaohui Tang(Shanxi Agricultural University), Hong Wu(Sichuan University), Yinghe Qiu(Second Military Medical University), Tianqiang Song(Tianjin Medical University Cancer Institute and Hospital), Jingbo Su(Xijing Hospital), Xianhai Mao(Hunan Provincial People's Hospital), Zhangjun Cheng(Zhongda Hospital Southeast University), Dong Zhang(Capital Medical University), Jingdong Li(Sun Yat-sen University), Yu He(Army Medical University), Zhimin Geng(Children's Hospital of Zhejiang University), Chen Chen(First Affiliated Hospital of Xi'an Jiaotong University), Wenlong Zhai(Zhengzhou University)
Cited by 0
Related Papers
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer
|Molecular Cancer|2022|652
Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
|Gut|2020|578
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial
|The Lancet. Gastroenterology & hepatology|2021|268